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ABSTRACT
Chemotherapeutic drug treatment can result in the emergence of drug-resistant 
cells. By culturing an interleukin-3 (IL-3)-dependent cell line, FL5.12 cells in the 
presence of the chemotherapeutic drug doxorubicin, we isolated FL/Doxo cells which 
are multi-drug resistant. Increased levels of drug efflux were detected in FL/Doxo 
cells which could be inhibited by the MDR1 inhibitor verapamil but not by the MRP1 
inhibitor MK571. The effects of TP53 and MEK1 were examined by infection of FL/
Doxo cells with retroviruses encoding either a dominant negative TP-53 gene (FL/
Doxo+ TP53 (DN) or a constitutively-activated MEK-1 gene (FL/Doxo + MEK1 (CA). 
Elevated MDR1 but not MRP1 mRNA transcripts were detected by quantitative RT-PCR 
in the drug-resistant cells while transcripts encoding anti-apoptotic genes such as: 
BCL2, BCLXL and MCL1 were observed at higher levels in the drug-sensitive FL5.12 
cells. The percentage of cells that were side-population positive was increased in 
the drug-resistant cells compared to the parental line. Drug-resistance and side-
positive population cells have been associated with cancer stem cells (CSC). Our 




RAF/MEK1/ERK, and TP53 pathways are critical in 
many biological processes including cancer progression 
and drug resistance. These pathways also exert pivotal 
roles in cell growth, death and senescence. The biological 
and biochemical effects of the Raf/MEK1/ERK, PI3K/
PTEN/AKT/mTORC1/GSK-3 and TP53 pathways have 
been recently reviewed [1–7]. These signaling cascades 
are also important in cardiovascular diseases, diabetes, 
metabolism, neurological diseases, obesity and other 
maladies [8–10]. A key factor controlled by both pathways 
positively and negatively is the mTORC complex which 
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is critical in regulating protein translation and is often 
dysregulated in various diseases [2, 4, 5, 7].
Dysregulation of the PI3K/PTEN/Akt/mTORC1/
GSK-3 pathway often occurs in human cancer. Certain 
members are thought of as oncogenes e.g., PI3K, AKT 
and GSK-3, while other members are considered to be 
tumor-suppressor genes e.g., PTEN and GSK-3 [11–30]. 
It is noted that GSK-3 can function as a tumor suppressor 
or an oncogene which might be due to the cell type or 
biological situation [1–6].
Inhibition of the PI3K/PTEN/AKT/mTORC/70S6K 
pathway by protein interacting with carboxyl terminus 
1 (PICT-1, a.k.a NOP53 ribosome biogenesis factor) 
can result in autophagy which results in cell death [31]. 
Serum-and glucocorticoid-induced protein kinase (SGK1) 
is related to AKT. Inhibition of SGK1 in glioblastoma 
cells can lead to cytotoxic autophagy [32]. Autophagy is a 
key process controlling cell death, cell fate and sensitivity 
to chemotherapeutic drugs, as well as, cancer [33–40].
The RAS/RAF/MEK/ERK pathway also consists of 
proteins which are considered as oncogenes, e.g., RAS, 
RAF and other proteins which may have tumor suppressor 
activities e.g., protein phosphatase 2A (PP2A), dual 
specificity protein phosphatase 1 (DUSP1) and others. 
The altered expression of components of this pathway can 
result in resistance to targeted therapeutics [33].
The TP53 pathway is critical in controlling many 
biological processes such as division, senescence, 
quiescence, geroconversion, autophagy, drug resistance 
and cancer induction [34–44]. Activation of autophagy 
can contribute to chemotherapeutic drug resistance [45]. 
The TP53 protein regulates many events and is involved 
in the regulation of microRNAs (miRs). The TP53 gene 
is frequently mutated in human cancer. In some cases, the 
mutations result in novel TP53 molecules which have gain 
of function activity [46].
Various classes of proteins are frequently implicated 
in resistance to chemotherapeutic drugs as well as targeted 
therapeutics. Prominent classes include proteins involved 
in signal transduction such as PI3K/PTEN/AKT/mTORC/
GSK-3, RAF/MEK/ERK, TP53 and BCL2 pathways 
[47–51]. The BCL2 family and other molecules which 
regulate apoptosis are also frequently deregulated in 
cancer and drug resistance [52–54]. The activity and levels 
of apoptotic regulatory proteins are often themselves 
regulated by the PI3K/PTEN/Akt/mTORC/GSK-3, Raf/
MEK/ERK, TP53 and other pathways by phosphorylation 
and transcriptional mechanisms [55–61].
Proteins that are frequently referred to as “drug-
transporters” are often upregulated in drug-resistant 
cells [62–64]. The “drug-transporting” functions of these 
proteins are often considered a “moon-lighting” activity 
of these proteins as they often have physiological roles in 
various organs (e.g., gut, colon) to transport xenobiotics 
[65–67].
Increased expression of MDR1 and/or MRP1 has 
been observed in certain drug-resistant hematopoietic cells 
such as HL-60 [68]. The MDR1 (a.k.a., Pgp, ABCB1) has 
been shown to efflux various chemotherapeutic drugs such 
as doxorubicin, daunorubicin, paclitaxel and others [69]. 
MRP1 (a.k.a. ABCC1) will transport various molecules 
including: daunorubicin, doxorubicin, edatrexate, 
etoposide, epirubicin, idarubicin, irinotecan, methotrexate, 
paclitaxel, vinblastine, vincristine and others [70]. Drug 
transporters may in some cases be regulated by miRs 
which in turn will change the sensitivity of certain tumors 
to chemotherapeutic drugs [71].
FL5.12 is an interleukin-3 (IL-3)-dependent 
hematopoietic cell line derived from the fetal liver of 
inbred mice [72]. They absolutely require IL-3 for their 
survival and after 18-24 hours of IL3-deprivation they 
commence to undergo apoptosis [73]. The IL3-dependency 
of these cells can be relieved after introduction of various 
activated oncogenes either by themselves (v-ABL, BCR-
ABL) [74] or in combination (AKT and RAF) [75]. In 
addition, activated cytokine genes such as IL-3 genes with 
mutations in the 3’untranslated region in the sequence 
motifs associated with mRNA (in)stability will relieve the 
dependency of these cells on the addition of exogenous 
IL-3 [76, 77]. FL5.12 cells do not normally cause tumors 
upon injection into nude immunocompromised mice, 
however, once their dependency on addition of exogenous 
IL-3 is abrogated, they usually will form tumors in 
immunocompromised mice [77, 78].
We derived a panel of doxorubicin-resistant FL5.12 
cells (FL/Doxo) by culturing them in the presence of 
doxorubicin for prolonged time periods [79]. These 
cells have been determined to have altered TP53 and 
ERK signaling. Furthermore, these cells show an altered 
response to certain small molecule inhibitors which target 
various molecules such as the mTORC1 complex [80]. We 
have previously shown that the doxorubicin-resistant FL/
Doxo cells are cross resistant to daunorubicin, paclitaxel 
but not 5-fluorouracil (5FU) [79]. We demonstrated 
recently that increased levels of mRNA transcripts 
encoding MDR1 but not MRP1 were detected by q-RT-
PCR in FL/Doxo in comparison to FL5.12 cells [80]. The 
drug-resistance of the FL/Doxo cells could be increased 
further by infection of the cells with retroviruses which 
encode either dominant negative (DN) TP53 (FL5.12 cells 
have wild-type TP53) or constitutively-active (CA) MEK1 
[79].
In the following studies, the drug efflux abilities 
of doxorubicin-resistant FL/Doxo and doxorubicin-
sensitive FL5.12 cells were determined, as well as, the 
presence of side-population positive cells in both types 
of cells. We document the effects of TP53(DN) and 
MEK1(CA) oncoproteins on drug-resistance and side-
population positive cells. These studies provide insights 
into mechanisms responsible for drug-resistance and side-
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positive population cells and may indicate approaches to 
target these cells which are often responsible for cancer 
development and progression.
RESULTS
IL-3 suppresses effects of doxorubicin in 
parental FL5.12 cells
The effects of doxorubicin were examined on the 
cytokine-dependent FL5.12 cells. When these cells were 
cultured in the presence of IL-3, the IC50 for doxorubicin 
was approximately 20 nM (Figure 1, Panel A). In 
contrast, when the cells were cultured in the absence 
of IL-3, the level of growth decreased and the IC50 for 
doxorubicin was approximately 3 nM (Figure 1, Panel 
A) which was 6.7-fold lower than when the cells were 
cultured in IL-3.
Doxorubicin-resistance of FL/Doxo and 
derivative cells
The doxorubicin-sensitivities of the FL5.12, FL/
Doxo, FL/Doxo + TP53(DN) and FL/Doxo + MEK1(CA) 
cells are presented in Figure 1, Panel B. In this experiment 
the doxorubicin IC50s for: FL5.12, FL/Doxo, FL/Doxo 
+ TP53(DN) and FL/Doxo + MEK1(CA) cells were 
approximately 12, 30, 100 and 55 nM respectively. These 
IC50s were all measured on the same day. There is some 
variation in IC50s measured on different days that is why 
it is better to make comparisons on results obtained on the 
same day.
Drug-resistant FL/Doxo cells are frequently 
larger cells than drug-sensitive FL5.12 cells
The morphologies of the FL5.12 and FL/Doxo cells 
were examined by phase contrast microscopsy (Figure 2). 
FL/Doxo cells (Panel B) were larger than parental FL5.12 
cells (Panel A). Often there were “giant” cells present in 
the FL/Doxo cultures [81]. Large multi-nucleate cells have 
been observed with drug-resistant prostate cancer cells 
[82].
Increasing concentrations of doxorubicin result 
in more apoptotic cells in drug-sensitive FL5.12 
than other drug-resistant FL5.12 cells
Doxorubicin-sensitive FL5.12 and doxorubicin-
resistant FL/Doxo, FL/Doxo + TP53 (DN) and FL/Doxo 
+ MEK1 (CA) cells were cultured with IL-3 + 10 nM 
doxorubicin (Figure 3) or IL-3 + 100 nM doxorubicin 
(Figure 4) for 24 hrs. Then the cells were stained with 
acridine orange and ethidium bromide and subsequently 
photographed. Upon culture with IL-3 + 10 nM 
doxorubicin, the drug-resistant cell cultures frequently 
contained larger cells (Figure 3, Panels B, C and D) in 
comparison to the FL5.12 cells (Figure 3, Panel A).
Figure 1: Effects of IL-3 on Sensitivity of FL5.12 cells to doxorubicin and sensitivies of FL5.12 and FL/Doxo cells to 
doxorubicin. (Panel A) The effects of IL-3 (solid red squares) and the absence of IL-3 (solid blue triangles) on the sensitivities of FL5.12 
cells to different concentrations doxorubicin and then examined by the 2-yl)-2,5-diphenyl tetrazolium bromide (MTT) assay as described 
[79, 80]. The MTT assay is a colorimetric assay that measures the reduction of MTT by mitochondrial succinate dehydrogenase as described 
[80]. Arrows pointing to the X-axis indicate where the IC50 can be estimated. Statistical analysis (unpaired t test results) indicated that the 
two-tailed P value: for (Panel A) FL5.12 in the presence of IL-3 and FL5.12 in the absence of IL-3 is less than 0.0001 which is considered 
to be extremely statistically significant. (Panel B) The effects of doxorubicin on: FL5.12 (solid red squares), FL/Doxo (solid blue upward 
triangles), FL/Doxo + TP53 (DN) (solid orange downward diamonds) and FL/Doxo + MEK1 (CA) (solid green diamonds) cells were 
determined by titrating all the cells on the same day with in the presence of IL-3 and then examined four days by MTT analysis. The P 
values for comparisons of FL5.12, FL/Doxo, FL/Doxo + TP53(DN) and FL/Doxo + MEK1(CA) are less than 0.0001 which are considered 
to be extremely statistical significant. These experiments were performed three times with similar results.
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Figure 2: Morphology of FL5.12 and FL/Doxo cells. The morphologies of (Panel A) FL5.12 and (Panel B) FL/Doxo cells were 
examined by phase microscopsy. The double-sided arrow in the cells is the same size in the different cells and serves to visualize how much 
larger some of the FL/Doxo cells are in comparison to the FL5.12 cells.
Figure 3: Morphology of FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) cells after staining with 
acridine orange and ethidium bromide. The morphologies of FL5.12 (Panel A), FL/Doxo (Panel B), FL/Doxo + TP53 (DN) (Panel 
C) and FL/Doxo + MEK1 (CA) (Panel D) were examined after staining the cells with acridine orange and ethidium bromide. All cells were 
cultured in the presence of IL-3 + 10 nM doxorubicin before staining and then microscopic examination. A 60X magnification is presented.
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Upon culture with IL-3 + 100 nM doxorubicin, the 
drug-sensitive FL5.12 cell cultures frequently contained 
a large number bright red apoptotic cells (Figure 4, Panel 
A) in comparison to the FL/Doxo cells (Figure 4, Panel 
B). This concentration of doxorubicin is above the IC50 
for FL5.12 cells.
Drug-resistant FL/Doxo cells display altered 
drug efflux activity
The abilities of the FL5.12 and FL/Doxo cells to 
efflux the dye rhodamine 123 (Table 1) were determined 
by drug efflux assays in the presence and absence of 
the MDR1 (Pgp, ABCB1) pump inhibitor verapamil or 
the MRP1 inhibitor MK571. Verapamil is a substrate 
of ABCB1 (MDR1) [83]. A FACS assay was used to 
quantitate drug efflux [83].
The background flouresence in FL/Doxo cells 
(25.9) was higher than that detected in FL5.12 cells (4.9). 
When the FL/Doxo cells were resuspended in medium 
containing verapamil, a value of 24.4 was observed while 
when FL5.12 cells were set up under similar conditions, a 
value of 6.8 was observed. Higher background levels were 
observed when the cells were incubated with the MRP1 
inhibitor, MK571 as a value of 43.3 was observed with the 
FL/Doxo cells and 29 was observed with the FL5.12 cells. 
These values decreased to 34.8 and 21.3 in the FL/Doxo 
and FL5.12 cells respectively at the T2 hr. time points.
Rhodamine 123 is effluxed by MDR1 [84]. 
Rhodamine 123 is effluxed to a lesser extent by MRP1 
Figure 4: Morphology of FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) cells after staining 
with acridine orange and ethidium bromide. The morphologies of FL5.12 (Panel A), FL/Doxo (Panel B), FL/Doxo + TP53 (DN) 
(Panel C) and FL/Doxo + MEK1 (CA) (Panel D) were examined after staining the cells with acridine orange and ethidium bromide. All 
cells were cultured in the presence of IL-3 + 100 nM doxorubicin before staining and then microscopic examination. A 60X magnification 
is presented.
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[85]. When FL5.12 cells were cultured in the presence of 
rhodamine, fluorescence values of 9,326.4 were observed 
at T0 hr. and 4,981 at the T2 hr. time point (Table 1). A 
ratio of 0.53. When FL5.12 cells were incubated with 
rhodamine 123 and verapamil, fluorescence values of 
2,042.4 and 3,330.8 were observed (a ratio of 1.63) 
indicating that verapamil prevented dye efflux at T2 hr. in 
rhodamine 123-treated FL5.12 cells.
When FL5.12 cells were incubated with MK571 
and rhodamine 123 values of 6861.2 were observed at 
T0 hr. while a value of 2740.5 was observed at the T2 
hr. incubation point (a ratio of 0.4). Thus, suppression of 
MRP1 with MK571 did not prevent total drug efflux.
When FL/Doxo cells were incubated with 
rhodamine 123, fluorescent values of 6,177.7 and 3,787.5 
were observed at the T0 hr. and T2 hr. time points 
respectively, a ratio of 0.61. When FL/Doxo cells were 
incubated with rhodamine 123 and verapamil, fluorescent 
values of 2,657.7 and 2,590.1 (a ratio of 0.97) at the 
T0 hr. and T2 hr. time points, indicating that verapamil 
inhibited rhodamine 123 efflux at the T2 hr. time point. 
More striking results were observed when FL/Doxo 
cells were incubated with rhodamine 123 and MK571 as 
fluorescence values of 4,029.1 were observed at the T0 hr. 
time point and 598.8 were seen at the T2 hr. time point, a 
ratio of 0.15. Thus, FL/Doxo cells, which express higher 
levels of MDR1 mRNA transcripts than FL5.12 cells (see 
Table 2) could efflux more rhodamine 123 than FL5.12 
cells (approximately 2.9-fold) upon treatment with the 
MRP1 inhibitor MK571.
Table 1: Abilities of FL5.12 and FL/Doxo cells to efflux rhodamine 1231
Cells Treatment T 0hr Point T 2hr Point Ratio Result
FL5.12 - 4.9 3.7 Background
FL5.12 Verapamil 6.8 6 Background
FL5.12 Rhodamine 123 9326.4 4981.1 0.53 Fluorescence decreased with time.
FL5.12 Rhodamine 123 +Verapamil 2042.4 3330.8 1.63 Verapamil inhibiting drug efflux.
FL5.12 MK571 29 21.3 Background
FL5.12 Rhodamine 123 + MK571 6861.2 2740.5 0.4 Verapamil inhibiting drug efflux.
FL/Doxo - 25.9 23.7 Background
FL/Doxo Verapamil 24.4 24.7 Background
FL/Doxo Rhodamine 123 6177.7 3787.5 0.61 Drug fluorescence decreased with time.
FL/Doxo Rhodamine + Verapamil 2657.7 2590.1 0.97
Fluorescence decreased 
compared to rhodamine 
123-alone treatment. 
Verapamil blocked 
further decrease in 
fluorescence. MDR1 
inhibited.
FL/Doxo MK571 43.3 34.8 Background
FL/Doxo Rhodamine 123 + MK571 4029.1 598.8 0.14
Fluorescence decreased 
compared to rhodamine 
123- alone treatment. 
MK571 inhibited drug 
efflux, MDR1 not 
inhibited. MDR1 able 
to pump rhodamine-123 
out. 6.7X less 
fluorescence.
1Drug efflux determine by FACS analysis as described by [83].
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Fold changes in MDR1 expression in 
doxorubicin-resistant FL/Doxo cells when 
normalized to doxorubicin-sensitive FL5.12 cells
The mRNA expression of MDR1 and MRP1 
molecules was examined previously in FL5.12, FL/Doxo, 
FL/Doxo+TP53(DN) and FL/Doxo+MEK1(CA) cells by 
q-RT-PCR [80]. The fold differences in the doxorubicin-
resistant FL/Doxo in comparison to the doxorubicin-
sensitive FL5.12 cells are summarized in Table 2.
The fold increase in MDR1 expression in the cells 
cultured presence of IL-3 ranged from 3.8-fold in FL/Doxo 
to 19.2-fold in FL/Doxo+MEK1(CA) cells. In contrast, 
the levels of MRP1 mRNA transcripts were similar in 
FL5.12 and FL/Doxo, when the cells were cultured in the 
presence of IL-3. In contrast, lower levels (2- and 1.8-fold 
respectively) of MRP1 mRNA transcripts were detected 
in FL/Doxo+TP53(DN) and FL/Doxo+MEK1(CA) cells 
respectively than in FL5.12 and FL/Doxo cells.
When the cells were cultured in the presence of 
IL-3 and 25 nM doxorubicin, the fold increase in MDR1 
transcripts in the doxorubicin-resistant cells in comparison 
with doxorubicin-sensitive FL5.12 cells ranged from 
between 8.6-fold in FL/Doxo cells to 99.7-fold in FL/
Doxo+MEK1(CA) cells. There were large increases in fold 
increase in MDR1 transcripts in FL/Doxo + MEK1(CA) 
cells cultured in the presence of doxorubicin. This stems 
from a 3.8-fold decrease in the levels of MDR1 mRNA 
transcripts detected in FL5.12 cells cultured in IL-3 and 
doxorubicin.
Upon culture of the cells in medium containing IL-3 
and doxorubicin, levels of MRP1 transcripts were similar 
in all four cell lines and ranged between 1.2-fold increase 
in FL/Doxo and FL/Doxo+MEK1(CA) cells and a 1.3-fold 
decrease in FL/Doxo+TP53(DN) cells in comparison to 
FL5.12 cells.
Effects of signal transduction inhibitors on 
sensitivity to doxorubicin in FL5.12 and drug 
resistant FL/Doxo derivative cells
The effects of titrating doxorubicin in the presence 
of the multi-kinase inhibitor sorafenib, which can 
inhibit RAF and other kinases, the MEK1 inhibitor 
(PD0325901), and the BCL2 inhibitor ABT737 were 
examined in Figures 5-7. In all of these graphs, the effects 
of suboptimal doses of the inhibitors and doxorubicin 
titrations were determined the same day. They are graphed 
in this manuscript to illustrate the differences between 
doxorubicin in the absence of inhibitor and doxorubicin 
in the presence of the inhibitor in the individual cell lines. 
In a previous manuscript, the effects of some of these and 
other inhibitors on the four different FL5.12-derived cell 
lines were plotted in the same graphs together [80].
FL5.12 cells were cultured in the presence of 
doxorubicin in the absence and presence of 500 nM of 
Table 2: Levels of MDR1 and MRP1 mRNA transcripts detected after qRT-PCR1
Cells Cultured with IL-3
Cells MDR1 
Transcripts




Fold compared to 
FL5.12
FL5.12 1.91±0.48 1 FL5.12 211±37.74 1









Cells Cultured with IL-3 + Doxorubicin
Cells MDR1 Transcripts




Fold compared to 
FL5.12
FL5.12 0.5±0.42 1 FL5.12 142.75±19.64 1











the multi-kinase inhibitor sorafenib (Figure 5, Panel A). 
An IC50 of approximately 20 nM was observed under 
both conditions. When FL/Doxo cells were cultured 
in the absence of doxorubicin, an IC50 of 120 nM was 
observed. Upon culture of FL/Doxo cells in the presence 
of doxorubicin and 500 nM sorafenib, the IC50 for 
doxorubicin was approximately 80 nM (Panel B).
When FL/Doxo + TP53(DN) cells were cultured 
in the absence of doxorubicin, an IC50 of 120 nM was 
observed. Upon culture of FL/Doxo +TP53(DN) in the 
presence of doxorubicin and 500 nM sorafenib, the IC50 for 
doxorubicin remained the essentially the same (Panel C).
When FL/Doxo + MEK1(CA) cells were cultured 
in the absence of doxorubicin, an IC50 of 120 nM was 
observed. Upon culture of FL/Doxo +TP53(DN) in the 
presence of doxorubicin and 500 nM sorafenib, the IC50 for 
doxorubicin remained the essentially the same (Panel D).
The effects of the MEK1 inhibitor PD0329501 on 
the doxorubicin IC50s were also examined. When FL5.12 
cells were cultured in the presence of 500 nM PD0329501 
MEK1 inhibitor, the IC50 did not change from when 
they were cultured in the absence of the MEK1 inhibitor 
(Figure 6, Panel A). Likewise, when FL/Doxo and FL/
Doxo + TP53(DN) cells were cultured in the presence 
and absence of 500 nM PD0325901 MEK inhibitor, the 
doxorubicin IC50s did not change (Figure 6, Panels B 
and C). In contrast, when FL/Doxo + MEK1(CA) cells 
were cultured in the presence of 500 nM PD0329501, 
the doxorubicin IC50 was approximately 100 nM while 
when the cells were cultured in the absence of the MEK1 
inhibitor, the doxorubicin IC50 was approximately 150 nM 
(Figure 6, Panel D). Thus, the MEK1 inhibitor treatment 
reduced the IC50 for doxorubicin approximately 1.5-fold in 
the FL/Doxo + MEK1(CA) cells.
The effects of the BCL2 inhibitor ABT737 on the 
doxorubicin IC50s were also examined (Figure 7). When 
FL5.12 cells were cultured in the presence of 500 nM ABT 
737 inhibitor, the level of growth decreased and the IC50 
for doxorubicin declined from 20 nM to 8 nM, a 2.5-fold 
decrease (Figure 7, Panel A). Likewise, when FL/Doxo, 
Figure 5: Effects of combination of the multi-kinase inhibitor sorafenib on the doxorubicin IC50 in FL5.12 and FL/
Doxo derivative cells. The effects of 500 nM sorafenib (solid blue circles) or no sorafenib (solid red squares) on the doxorubicin-
sensitivity of: (Panel A) FL5.12 cells, (Panel B) FL/Doxo cells, (Panel C) FL/Doxo + TP53 (DN) cells or (Panel D) FL/Doxo + MEK1 
(CA) cells were determined by titrating all the cells on the same day. Arrows pointing to the X-axis indicate where the IC50 can be estimated. 
Statistical analysis (unpaired t test results) indicated that the two-tailed P values for FL/Doxo treated with doxorubicin or doxorubicin and 
sorafenib in (Panel B) is 0.0046 which is considered to be very statistically significant. These experiments were performed three times with 
similar results.
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FL/Doxo + TP53(DN) and FL/Doxo + MEK1(CA) cells 
were cultured in the presence and absence of 500 nM ABT-
737 (Figure 7, Panel B, C, and D), the level of growth 
decreased substantially and the doxorubicin IC50s decreased 
from 180 nM to 8 nM (22.5-fold) in FL/Doxo cells, from 
130 nM to 18 nM (7.2-fold) in FL/Doxo + TP53(DN) cells 
and from 160 to 2 nM (80-fold) in FL/Doxo + MEK1(CA) 
cells. Thus the BCL2 inhibitor decreased the amount of 
doxorubicin required to achieve the IC50.
Effects of combination of signal transduction 
and BCL2 inhibitors on FL5.12 and FL/Doxo 
derivative cells
The effects of combining sorafenib with the BCL2 
inhibitor ABT737 were examined in Figure 8. When 
FL5.12 cells were cultured in the presence of the multi-
kinase sorafenib inhibitor, an IC50 of 5,000 nM was 
observed (Figure 8, Panel A). In contrast, when they were 
incubated with sorafenib in the presence of 500 nM ABT-
737 inhibitor, the level of growth decreased and an IC50 
of approximately 65 nM (77-fold decrease) was observed.
When FL/Doxo cells were cultured in the presence 
of sorafenib, an IC50 was not obtained even with 
concentrations up to 5,000 nM (Figure 8, Panel B). In 
contrast, the level of growth decreased when FL/Doxo 
cells were cultured with sorafenib in the presence of 500 
nM ABT-737 inhibitor and an IC50 of approximately 3 nM 
(approximately a 1,666-fold decrease) with respect to the 
sorafenib inhibitor was observed.
When FL/Doxo + TP53 (DN) cells were cultured 
in the presence of sorafenib, the IC50 was not obtained 
even with doses of 5,000 nM doxorubicin (Figure 8, 
Panel C). In contrast, the level of growth decreased 
when FL/Doxo + TP53(DN) cells were cultured with 
sorafenib in the presence of the BCL2 inhibitor and an 
IC50 of approximately 2,000 nM sorafenib was observed. 
When FL/Doxo + MEK1(CA) cells were cultured in the 
Figure 6: Effects of combination of the MEK1 inhibitor PD0325901 on the doxorubicin IC50 in FL5.12 and FL/
Doxo derivative cells. The effects of 500 nM PD0325901 (solid blue circles) or no PD0325901 (solid red squares) on the doxorubicin-
sensitivity of: (Panel A) FL5.12 cells, (Panel B) FL/Doxo cells, (Panel C) FL/Doxo + TP53 (DN) cells or (Panel D) FL/Doxo + MEK1 
(CA) cells were determined by titrating all the cells on the same day. Arrows pointing to the X-axis indicate where the IC50 can be estimated. 
Statistical analysis (unpaired t test results) indicated that the two-tailed P values for FL/Doxo + MEK1 (CA) treated with doxorubicin 
or doxorubicin and the MEK inhibitor in (Panel D) is 0.0157 and is considered to be statistically significant. These experiments were 
performed three times with similar results.
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presence of sorafenib, an IC50 was not observed even with 
concentrations of 5,000 nM sorafenib (Figure 8, Panel D). 
Addition of the BCL2 inhibitor decreased growth and an 
IC50 of approximately 4,000 nM sorafenib was observed. 
In the FL/Doxo + MEK1(CA) cells, the decrease was 
not observed until approximately 100 nM sorafenib, 
demonstrating that the FL/Doxo + MEK1(CA) cells were 
more resistant to the BCL2 inhibitor than the other cells.
Essentially the reciprocal experiments were 
performed. Namely, the effects of titrating cells with the 
BCL2 inhibitor in the presence and absence of 500 nM 
sorafenib (Figure 9). Addition of 500 nM sorafenib did 
not increase the effect of the BCL2 inhibitor on FL5.12 
cells (Figure 9, Panel A). When FL/Doxo and FL/Doxo 
+ TP53(DN) cells were treated with 500 nM sorafenib 
and titrated with the BCL2 inhibitor, the IC50s decreased 
from 40 to 10 nM (4-fold) in FL/Doxo (Panel B) and from 
170 to 130 nM (1.3-fold) in FL/Doxo + TP53(DN) cells 
respectively (Panels B and C). Treatment of the FL/Doxo 
+ MEK1(CA) cells with up to 5,000 nM BCL2 inhibitor 
did not reach an IC50. Combined treatment with different 
doses of the BCL2 inhibitor and 500 nM sorafenib reduced 
cell growth but did not reduce the IC50 for the BCL2 
inhibitor. The experiments mirror the results presented in 
Figure 8 and document that the FL/Doxo + MEK1(CA) 
cells were more resistant to the BCL2 inhibitor than the 
other FL5.12 and FL/Doxo-derived cells.
When FL5.12 cells were cultured in the presence of 
the PD0329501 MEK1 inhibitor, an IC50 was not obtained 
even with concentrations up to 5,000 nM (Figure 10, Panel 
A). In contrast, the level of growth decreased when they 
were cultured with the MEK1 inhibitor in the presence of 
500 nM ABT-737 inhibitor and an IC50 of approximately 
100 nM with respect to the MEK1 inhibitor was observed.
When FL/Doxo cells were cultured in the presence 
of the PD0329501 MEK1 inhibitor, an IC50 was not 
obtained even with concentrations up to 5,000 nM (Figure 
10, Panel B). In contrast, the level of growth decreased 
Figure 7: Effects of combination of the BCL2 inhibitor ABT-737 on the doxorubicin IC50 in FL5.12 and FL/Doxo 
derivative cells. The effects of 500 nM ABT-737 (solid blue circles) or no ABT-737 (solid red squares) on the doxorubicin-sensitivity of: 
(Panel A) FL5.12 cells, (Panel B) FL/Doxo cells, (Panel C) FL/Doxo + TP53 (DN) cells or (Panel D) FL/Doxo + MEK1 (CA) cells were 
determined. Arrows pointing to the X-axis indicate where the IC50 can be estimated. Statistical analysis (unpaired t test results) indicated 
that the two-tailed P values for the various cells treated with doxorubicin or doxorubicin and the BCL2 inhibitor in: (Panels A-D) are less 
than 0.0001 which are considered to be extremely statistical significant. These experiments were performed three times with similar results.
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when FL/Doxo cells were cultured with the MEK1 
inhibitor in the presence of 500 nM ABT-737 inhibitor and 
an IC50 of approximately 3 nM with respect to the MEK1 
inhibitor was observed.
When FL/Doxo + TP53 (DN) cells were cultured in 
the presence of the PD0329501 MEK1 inhibitor, an IC50 of 
approximately 3,000 nM was observed (Figure 10, Panel 
C). The level of growth decreased slightly when FL/Doxo 
+ TP53(DN) cells were cultured with the MEK1 inhibitor 
in the presence of 500 nM ABT-737 inhibitor, but the IC50 
for the MEK1 inhibitor was not obtained even with doses 
of 5,000 nM PD0329501.
When FL/Doxo + MEK1(CA) were cultured in the 
presence of the PD0329501, an IC50 of approximately 400 
nM MEK1 inhibitor was observed (Figure 10, Panel D). 
In contrast, the addition of 500 nM BCL2 inhibitor did not 
decrease the concentration of the MEK1 inhibitor required 
to reach the IC50, if anything, it antagonized slightly with 
the MEK1 inhibitor in FL/Doxo + MEK1(CA) cells.
Essentially the reciprocal experiments were 
performed. Namely, the effects of titrating cells with the 
BCL2 inhibitor in the presence and absence of the 500 nM 
MEK1 inhibitor were determined (Figure 11). Addition of 
500 nM MEK inhibitor did not reduce the effect of the 
BCL2 inhibitor on FL5.12 cells (Figure 11, Panel A). 
When FL/Doxo and FL/Doxo + TP53(DN) cells were 
treated with 500 nM MEK inhibitor and titrated with the 
BCL2 inhibitor, the IC50s decreased from 55 to 45 nM 
(1.2-fold) in FL/Doxo (Panel B) and from 120 to 70 nM 
(1.7-fold) in FL/Doxo + TP53(DN) cells respectively 
(Panels B and C). In contrast, a more significant result 
was observed in FL/Doxo + MEK1(CA), the IC50 for the 
BCL2 inhibitor dropped from greater than 5,000 nM to 
approximately 20 nM. The experiments mirror the results 
presented in the previous figure and document that the 
FL/Doxo + MEK1(CA) cells are sensitive to the MEK1 
inhibitor while resistant to the BCL2 inhibitor. In contrast 
the FL/Doxo, FL/Doxo + TP53(DN) and FL5.12 cells are 
Figure 8: Effects of combination of the BCL2 inhibitor ABT-737 on sorafenib IC50 in FL5.12 and FL/Doxo derivative 
cells. The effects of 500 nM ABT-737 (solid blue circles) or no ABT-737 (solid red squares) on the sorafenib inhibitor-sensitivity of: 
(Panel A) FL5.12 cells, (Panel B) FL/Doxo cells, (Panel C) FL/Doxo + TP53 (DN) cells or (Panel D) FL/Doxo + MEK1 (CA) cells were 
determined by titrating all the cells on the same day. Arrows pointing to the X-axis indicate where the IC50 can be estimated. Statistical 
analysis (unpaired t test results) indicated that the two-tailed P values for the various cells treated with doxorubicin or doxorubicin and 
the BCL2 inhibitor in: (Panel A) is less than 0.0001 which is considered to be extremely statistically significant. These experiments were 
performed three times with similar results.
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more sensitive to the effects of the BCL2 inhibitor than the 
MEK1 inhibitor.
Drug-resistant FL/Doxo cells displayed increased 
levels of side-population positive cells
The presence of side-population positive cells in the 
FL5.12 and different FL/Doxo cells was examined. Side-
population positive cells is often associated with drug-
resistance and CSCs [86]. MDR1 expression has been 
shown to be important in glioma CSCs [87]. Verapamil 
has been shown to inhibit tumor progression by targeting 
the side population of certain types of cancer cells [88].
Side-population positive cells were detected as we 
and others have previously described [88–90]. Statistically 
significant higher levels of side-population positive cells were 
detected by FACSs analysis in FL/Doxo than in FL5.12 cells 
(Figure 12). Approximately 1.9-fold more side population 
positive cells were detected in FL/Doxo cells than in FL5.12 
cells. The detection of side population positive cells was 
prevented with the FL5.12 and FL/Doxo cells were treated 
with 25 nM verapamil which inhibits MDR1.
The presence of side-population positive cells in 
the FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) 
cells was also examined in the same experiments (Figure 
12). Increased levels of side-population positive cells were 
detected in the FL/Doxo + TP53 (DN) and FL/Doxo + 
MEK1 (CA) cells than in either FL/Doxo or FL5.12 cells. 
Approximately 3- and 4.5-fold more side-positive cells 
were detected in FL/Doxo + TP53 (DN) and FL/Doxo 
+ MEK1 (CA) cells than in FL5.12 cells. In contrast to 
the results observed with FL/Doxo and FL5.12 cells, 
the percentage of side-population positive FL/Doxo + 
TP53 (DN) and FL/Doxo + MEK1 (CA) cells was not 
as inhibited in FL/Doxo and FL5.12 cells after 25 nM 
verapamil treatment.
Figure 9: Effects of combination of the multi-kinase inhibitor sorafenib on the BCL2 inhibitor ABT-737 IC50 in 
FL5.12 and FL/Doxo derivative cells. The effects of 500 nM sorafenib (solid blue circles) or no sorafenib (solid red squares) 
on the BCL2 inhibitor-sensitivity of: (Panel A) FL5.12 cells, (Panel B) FL/Doxo cells, (Panel C) FL/Doxo + TP53 (DN) 
cells or (Panel D) FL/Doxo + MEK1 (CA) cells were determined by titrating all the cells on the same day. Arrows pointing 
to the X-axis indicate where the IC50 can be estimated. Statistical analysis (unpaired t test results) indicated that the two-
tailed P values for the various cells treated with BCL2 inhibitor or BCL2 and sorafenib inhibitors in: (Panel B) is 0.0006 
which is considered to be extremely statistically significant, (Panel C) is 0.0290 which is considered to be significant. These 
experiments were performed three times with similar results.
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DISCUSSION
The cytokine IL-3 was protective in FL5.12 
cells against the effects of doxorubicin. When FL5.12 
cells were cultured in the absence of IL-3, the IC50 was 
approximately 6.7-fold less than when they were grown in 
the presence of IL-3. FL5.12 cells will undergo apoptosis 
when they are cultured in the absence of IL-3 [75, 79, 
81]. Upon their incubation in the absence of IL-3 in 
the presence of doxorubicin, their growth is even more 
inhibited than when they are cultured in the presence of 
IL-3 and doxorubicin. Doxorubicin-resistant FL/Doxo 
cells often were larger than doxorubicin-sensitive FL/
Doxo cells and acridine orange staining has indicated that 
they are often multi-nucleate [81].
Doxorubicin induced more apoptosis in the 
doxorubicin-sensitive cells at lower doxorubicin 
concentrations than in the doxorubicin-resistant cells 
[79]. Similar results were observed with daunorubicin 
and paclitaxel with the FL5.12 and FL/Doxo cells 
[79]. Previously we demonstrated that there was 
decreased caspase activation (caspases 3, 8 and 10) 
in the doxorubicin-resistant FL/Doxo cells than in the 
doxorubicin-sensitive FL5.12 cells after doxorubicin 
treatment [79]. In this current manuscript, we have focused 
on drug efflux, the effects of the MDR1 and the MRP1 
inhibitors on drug efflux, drug transporter gene expression, 
and the effects of signal transduction and BCL2 inhibitors 
on growth, and the presence of side-population positive 
cells in drug-sensitive and drug-resistant cells.
Both FL5.12 and FL/Doxo cells could readily efflux 
rhodamine 123. In both FL5.12 and FL/Doxo cells, the 
level of fluorescence detected after rhodamine 123 staining 
decreased after 2 hrs. on ice. The efflux of rhodamine 123 was 
inhibited in both FL5.12 and FL/Doxo cells after verapamil 
treatment. In contrast, after treatment with the MK571 MRP1 
inhibitor, the efflux of rhodamine 123 was not as inhibited. 
The FL/Doxo cells appeared to efflux approximately 2.9-fold 
more rhodamine 123 than the FL5.12 cells when they were 
treated with the MK571 MRP1 inhibitor.
Figure 10: Effects of combination of the BCL2 inhibitor ABT-737 on the MEK inhibitor PD0325901 IC50 in FL5.12 
and FL/Doxo derivative cells. The effects of 500 nM ABT-737 (solid blue circles) or no ABT-737 (solid red squares) on the MEK 
inhibitor-sensitivity of: (Panel A) FL5.12 cells, (Panel B) FL/Doxo cells, (Panel C) FL/Doxo + TP53 (DN) cells or (Panel D) FL/Doxo 
+ MEK1 (CA) cells were determined by titrating all the cells on the same day in the absence and presence of the BCL2 inhibitor. Arrows 
pointing to the X-axis indicate where the IC50 can be estimated. These experiments were performed three times with similar results.
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The levels of mRNAs of MDR1 and MRP1 have 
been quantitated by qRT-PCR [80]. In this current 
manuscript we discuss the fold differences in mRNA 
expression. The cell lines with the highest degree 
of drug-resistance, FL/Doxo+TP53(DN) and FL/
Doxo+MEK1(CA) expressed approximately 10-100-fold 
more MDR1 mRNA transcripts than in the drug-sensitive 
FL5.12 cells. FL/Doxo cells expressed approximately 
4-fold more MDR1 transcripts than FL5.12 cells. The fold 
differences in MDR1 expression between the doxorubicin-
sensitive FL5.12 cells and doxorubicin-resistant FL/Doxo 
and derivative cells increased when the cells were cultured 
in the presence of doxorubicin as the levels of MDR1 
mRNAs detected in the FL5.12 cells decreased.
In contrast, 2- to 4-fold less BAX, BIM, BCL2 
and BIM mRNAs and between 1.3 to 2-fold less MCL1 
mRNA transcripts were detected in the cells with the 
highest-degree of drug-resistance, FL/Doxo+TP53(DN) 
and FL/Doxo+MEK1(CA) than in the drug-sensitive 
FL5.12 cells [80]. The FL/Doxo cells expressed 2-4-fold 
less BCL2 mRNA transcripts than the FL5.12 cells. The 
FL/Doxo cells were very sensitive to the BCL2/BCLXL 
inhibitor ABT-737 [80]. Our results with the expression of 
the anti-apoptotic BCL2 and BCLXL mRNA expression 
were interesting as the cells that were more doxorubicin-
sensitive expressed more of these transcripts as detected 
by q-RT-PCR. Thus, in our system, doxorubicin-resistance 
is associated with lower expression of BCL2 and BCLXL 
RNA expression. Previously we determined that ectopic 
expression of BCL2 could enhance the ability of the 
RAF and MEK1 oncoproteins to abrogate the cytokine-
dependence of IL3-dependent cells [91, 92].
Our results indicate the MEK1(CA) and the 
TP53(DN) genes can have effects on both the expression 
of MDR1 and the presence of side-population positive 
cells. These results are important as these characteristics 
Figure 11: Effects of combination of the MEK inhibitor PD0325901 on the BCL2 inhibitor ABT-737 IC50 in FL5.12 
and FL/Doxo derivative cells. The effects of 500 nM PD0325901 (solid blue circles) or no PD0325901 (solid red squares) on the 
BCL2 inhibitor-sensitivity of: (Panel A) FL5.12 cells, (Panel B) FL/Doxo cells, (Panel C) FL/Doxo + TP53 (DN) cells or (Panel D) FL/
Doxo + MEK1 (CA) cells were determined by titrating all of the cells on the same day in the absence and presence of the MEK inhibitor. 
Arrows pointing to the X-axis indicate where the IC50 can be estimated. Statistical analysis (unpaired t test results) indicated that the two-
tailed P values for the various cells treated with BCL2 or BCL2 and MEK1 inhibitor in: (Panel B) is 0.0073 which is considered to be 
very statistically significant, (Panel C) is less than 0.0011 which is considered to be very statistically significant. These experiments were 
performed three times with similar results.
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are often linked with CSC. CSCs have been detected in 
almost every cancer type. Novel methods to target CSCs 
are under intense investigation. Other studies have shown 
the side-population positive cells includes CSCs [93]. 
Chemotherapeutic drug-resistance is often associated 
with drug transporters, side-population positive and 
CSCs [86]. Other investigators have documented the 
sensitivity of other cancer cells to verapamil treatment 
and their enhanced abilities to form colony in vitro and 
tumors in animals [94]. In the above study, the presence 
of side-population positive AsPC1 pancreatic cancer cells 
was not eliminated completely after verapamil treatment. 
These and our results indicate that there may be other drug 
transporters not inhibited by verapamil that are present in 
some of the cells which contribute to their side-population 
positive cells and drug resistance. Alternatively, the 
concentration of verapamil used may not have been 
sufficient to inhibit all the MDR1 molecules expressed in 
the drug-resistant cells.
An effect of sorafenib on the sensitivity to 
doxorubicin was observed in FL/Doxo but not in the 
other FL/Doxo derivative or parental FL5.12 cells. In 
most experiments, the FL/Doxo are more sensitive to 
doxorubicin, than either FL/Doxo + TP53(DN) or FL/
Doxo + MEK1(CA) cells. In these studies, addition of 
500 nM PD0325901 MEK inhibitor only affected the 
doxorubicin IC50 in FL/Doxo + MEK1(CA) cells. In 
contrast, addition of 500 nM ABT-737 BCL2 inhibitor 
reduced both the level of cell growth and the doxorubicin 
IC50 in FL5.12, FL/Doxo and FL/Doxo +TP53(DN) and 
FL/Doxo + MEK1(CA) cells. Thus, the ABT-737 BCL2 
inhibitor could reduce the IC50 for doxorubicin in all cell 
lines. In contrast, the FL/Doxo+ MEK1(CA) cells were 
relatively resistant to the BCL2 inhibitor by itself or in 
combination with certain signal transduction inhibitors.
The PI3K/PTEN/AKT/mTORC1/GSK-3 pathway 
regulates the expression of various drug transporter 
molecules [95–97]. The PI3K/PTEN/AKT/mTORC1/
Figure 12: Presence of side-positive cells in FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and FL/Doxo + MEK1 (CA) 
cells. The presence of side-positive cells was determined by FACS analysis. In some cases, the cells were cultured with 25 nM verapamil. 
Statistical analysis (unpaired t test results) indicated that the two-tailed P value for the FL5.12 (no verapamil) and FL/Doxo (no verapamil) 
is 0.0195 which is considered to be statistically significant. Statistical analysis (unpaired t test results) indicated that the two-tailed P value 
for the FL5.12 (plus verapamil) and FL/Doxo (plus verapamil) is 0.2879 which is not statistically significant. Statistical analysis (unpaired 
t test results) indicated that the two-tailed P value for the FL5.12 (no verapamil) and FL/Doxo + TP53(DN) (no verapamil) is 0.0005 which 
is considered to be extremely statistically significant. Statistical analysis (unpaired t test results) indicated that the two-tailed P value for 
the FL5.12 (plus verapamil) and FL/Doxo + TP53 (DN) (plus verapamil) is 0.0001 which is considered extremely statistically significant. 
Statistical analysis (unpaired t test results) indicated that the two-tailed P value for the FL5.12 (no verapamil) and FL/Doxo + MEK1(CA) 
(no verapamil) is 0.0013 which is considered to be very statistically significant. Statistical analysis (unpaired t test results) indicated that the 
two-tailed P value for the FL5.12 (plus verapamil) and FL/Doxo + MEK1 (CA) (plus verapamil) is 0.0002 which is considered extremely 
statistically significant.
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GSK-3 pathway can induce multidrug-resistance in AML 
cells that were co-cultured with stromal cells [98].
Various signaling pathways have been implicated 
in drug resistance, both resistance to classical 
chemotherapeutic drugs, as well as, targeted therapeutics. 
Often resistance is associated with CSCs and CSCs 
frequently display altered activity of proteins which 
transport drugs. Our studies have documented the 
importance of activated MEK1 in drug-resistance and 
side-population positive cells in hematopoietic cells.
Parental FL5.12 and FL/Doxo + TP53(DN) cells 
were also sensitive to the BCL2 inhibitor, but the FL/Doxo 
+ MEK1(CA) cells were relatively resistant to the BCL2 
inhibitor ABT-737. It is possible that the activated MEK1 
present in the FL/Doxo + MEK1(CA) cells, activated 
ERK1,2 which phosphorylated a BCL2 family member 
which prevented the effects of the BCL2 inhibitor. 
Importantly, the doxorubicin-sensitivity of all the cell lines 
examined could be reduced upon treatment with the BCL2 
inhibitor.
Various BCL2 family members have been observed 
to be phosphorylated by RAF/MEK/ERK signaling 
which could have various effects on apoptosis, cellular 
proliferation, prevention of apoptosis and drug-resistance 
[99–106]. Interactions between RAF/MEK/ERK and 
BCL2 family members have been shown to abrogate the 
cytokine-dependency of certain hematopoietic cells [91, 
92]. BCL2 inhibitors increased the sensitivity of the cells 
to doxorubicin in the current study. Inhibition of RAF/
MEK/ERK signaling by sorafenib also had some effects 
on the doxorubicin-sensitivity of FL/Doxo cells.
Mutation of TP53 may also contribute to drug-
resistance and CSCs. We have demonstrated that 
introduction of the DN-TP53 gene into FL/Doxo cells 
resulted in more drug- resistance and increased side-
population positive cells. Inheritance of DN-TP53 also 
resulted in decreased anti-apoptotic and pro-apoptotic 
BCL2 family expression. In contrast, inheritance of DN-
TP53 resulted in increased levels of beta2-microglobulin 
mRNA transcripts [80]. Interestingly, FL/Doxo + TP53 
(DN) cells were very sensitive to the BCL-2 inhibitor, 
ABT-737. These cells were relatively resistant to MEK1 
inhibitor PD0329501. Addition of 500 nM MEK inhibitor 
to cells titrated with the BCL2 inhibitor decreased the IC50 
required for the BCL2 inhibitor less than 2-fold.
Similar experiments performed with the 
combination of the MEK1 inhibitor and titration with the 
BCL2 inhibitor in FL/Doxo + MEK1(CA) cells reduced 
the IC50 for the amount of BCL2 inhibitor approximately 
500-fold. While FL/Doxo + TP53(DN) cells expressed 
high levels of MDR1 as did FL/Doxo + MEK1(CA) cells, 
but they differed in their sensitivities to BCL2 and MEK1 
inhibitors.
In conclusion, our studies document the effects of 
signaling pathways and TP53 on the drug-resistance of 
hematopoietic cells. By using a single parental cell line 
and three drug resistant derivatives of it which either have 
or lack TP53 (DN) or MEK1(CA), we can identify some 
of the key components in resistance to doxorubicin a 
common, clinically used chemotherapeutic drug. Namely 
increased expression of MDR1 and altered BCL2 family 
member expression which contribute to altered sensitivity 
to doxorubicin as well as targeted therapeutics. Our results 
may have clinical significance as some of the drugs and 
signal transduction inhibitors and their next generation 
counter-parts are being used to treat various cancers.
MATERIALS AND METHODS
Cells and tissue culture conditions
FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and 
FL/Doxo + MEK1 (CA) were derived as described [72, 
79–81]. The cells were cultured in RPMI containing 
antibiotics, l-glutamine 10% fetal bovine serum and 10% 
WEHI-3B supernatant as a source of murine IL-3 as 
described [78–81].
Treatment of cells with signal transduction 
inhibitors and doxorubicin
FL5.12, FL/Doxo, FL/Doxo + TP53 (DN) and FL/
Doxo + MEK1 (CA) were titrated with the different signal 
transduction inhibitors and doxorubicin as described [79–
81]. Statistical analysis was performed using GraphPad 
Prism. MTT proliferation assays were performed as 
described [79–81].
Drug efflux assays
Drug Efflux assays were performed by FACS 
analysis as described previously [83].
Side population analysis
Side population analysis was performed as described 
[88–90]. Briefly, FL5.12, FL/Doxo, FL/Doxo + TP53(DN) 
and FL/Doxo + MEK1(CA) Cells were resuspended at 1 
× 106/mL in RPMI 1640 with 10% FBS and 10% WEHI-
3B supernatant in the presence and absence of 25 nM 
verapamil. Hoechst 33342 dye (Sigma-Aldrich, Saint 
Louis, Missouri) was added to a final concentration of 5 
μg/mL. The cells were incubated at 370C for 90 minutes. 
Cells were then centrifuged and the pellet resupended in 
cold PBS containing 2% FBS. Cells were counterstained 
with propidum iodide (10 μg/ml). Hoechst dye was excited 
at 355 nM. The side-population positive analysis was then 
performed as described [88–90] on a BD FACSVantage. 
The side-population population, essentially disappeared 
in FL5.12 and FL/Doxo cells when they were cultured 
in the presence of verapamil. Experiments were set up in 
triplicate in 6-well plates.
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Quantitative RT-PCR and normalization to 
FL5.12 cells
TaqMan Gene Expression assays were described 
previously [80]. Levels of mRNA transcripts were 
normalized to the levels of the particular gene transcripts 
detected in FL5.12 cells which was set at 1.
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